@article{4e4b560af8b54aa592e692b779dcc9d7,
title = "A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa",
abstract = "Hidradenitis suppurativa (HS) has an impact on patients' quality of life. Treatment of HS is generally unsatisfactory, thus new treatments are needed.",
keywords = "Adult, Anti-Inflammatory Agents, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Double-Blind Method, Female, Hidradenitis Suppurativa, Humans, Injections, Subcutaneous, Male, Middle Aged, Pain, Pain Measurement, Prospective Studies, Quality of Life, Treatment Outcome",
author = "I Miller and Carina Lynggaard and Lophaven, {S{\o}ren Nymand} and Zachariae, {Claus Otto Carl} and Dufour, {D N} and Jemec, {G B E}",
note = "{\textcopyright} 2011 The Authors. BJD {\textcopyright} 2011 British Association of Dermatologists 2011.",
year = "2011",
doi = "10.1111/j.1365-2133.2011.10339.x",
language = "English",
volume = "165",
pages = "391--8",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "2",
}